Abstract
Regular consumption of natural antioxidants reduces the risk of developing diseases. Aloin is one of the main active phenolic components of Aloe vera. The main disadvantage of aloin is its concentration limit of use that causes cell damage. One of the aims of this study was to investigate the antioxidant activity of aloin in the presence and absence of camel β-casein (β-CN) and its peptide fractions. The mixture of aloin,β-CN and peptides showed a very high antioxidant activity in a synergistic manner as compared to each component alone. The alpha (α)-glucosidase inhibitory activity of aloin was also investigated in the presence and absence of β-CN and its peptides. Aloin alone is a potent inhibitor of α-glucosidase. The α-glucosidase inhibitory activity of aloin is reduced in the presence of β-CN or its peptides. The combination of aloin and β-CN or its peptides makes a high antioxidant functional ingredient.
Keywords: Alpha (α)-Glucosidase, Aloe vera components, aloin, camel β-casein, hydrolysates, inhibitory action, natural antioxidants
Protein & Peptide Letters
Title:Synergic Study of α-Glucosidase Inhibitory Action of Aloin and its Antioxidant Activity with and without Camel β-Casein and its Peptides
Volume: 20 Issue: 5
Author(s): F. Ghamari, S. M. Ghaffari, M. Salami, F. Moosavi-Movahedi, F. Farivar, A. Johari, A. A. Saboury, J. M. Chobert, T. Haertle and A. A. Moosavi-Movahedi
Affiliation:
Keywords: Alpha (α)-Glucosidase, Aloe vera components, aloin, camel β-casein, hydrolysates, inhibitory action, natural antioxidants
Abstract: Regular consumption of natural antioxidants reduces the risk of developing diseases. Aloin is one of the main active phenolic components of Aloe vera. The main disadvantage of aloin is its concentration limit of use that causes cell damage. One of the aims of this study was to investigate the antioxidant activity of aloin in the presence and absence of camel β-casein (β-CN) and its peptide fractions. The mixture of aloin,β-CN and peptides showed a very high antioxidant activity in a synergistic manner as compared to each component alone. The alpha (α)-glucosidase inhibitory activity of aloin was also investigated in the presence and absence of β-CN and its peptides. Aloin alone is a potent inhibitor of α-glucosidase. The α-glucosidase inhibitory activity of aloin is reduced in the presence of β-CN or its peptides. The combination of aloin and β-CN or its peptides makes a high antioxidant functional ingredient.
Export Options
About this article
Cite this article as:
Ghamari F., M. Ghaffari S., Salami M., Moosavi-Movahedi F., Farivar F., Johari A., A. Saboury A., M. Chobert J., Haertle T. and A. Moosavi-Movahedi A., Synergic Study of α-Glucosidase Inhibitory Action of Aloin and its Antioxidant Activity with and without Camel β-Casein and its Peptides, Protein & Peptide Letters 2013; 20 (5) . https://dx.doi.org/10.2174/0929866511320050015
DOI https://dx.doi.org/10.2174/0929866511320050015 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Rationale for Combined Therapy with a Calcium Channel Blocker and a Statin: Evaluation of Basic and Clinical Evidence
Current Drug Targets - Cardiovascular & Hematological Disorders Combinational Approaches Targeting Neurodegeneration, Oxidative Stress, and Inflammation in the Treatment of Diabetic Retinopathy
Current Drug Targets Current Therapeutic Concepts in Peripartum Cardiomyopathy
Current Pharmaceutical Design Patent Selections :
Recent Patents on CNS Drug Discovery (Discontinued) Editorial [Hot Topic: Recent Progress in the Development of Anti-Diabetic Drugs (Guest Editor: J. Eckel)]
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Animal Models of Atherosclerosis Progression: Current Concepts
Current Drug Targets - Cardiovascular & Hematological Disorders Neuropeptides as Therapeutic Targets in Anxiety Disorders
Current Pharmaceutical Design Factors Influencing the Hemodynamic and Metabolic Effects of Insulin in Muscle
Current Diabetes Reviews Anti-Endothelial Cell Antibodies in Patients with Cerebral Small Vessel Disease
Current Neurovascular Research Chromogranin-A: A Multifaceted Cardiovascular Role in Health and Disease
Current Medicinal Chemistry Hypothyroidism and Cardiovascular Disease: Factors, Mechanism and Future Perspectives
Current Medicinal Chemistry Spin Trapping: An Essential Tool for the Study of Diseases Caused by Oxidative Stress
Current Topics in Medicinal Chemistry Patent Selections
Recent Patents on DNA & Gene Sequences Vitamins in Heart Failure: Friend or Enemy?
Current Pharmaceutical Design Is Metabolic Syndrome Associated to HIV Infection Per Se? Results from the HERMES Study
Current HIV Research Inflammatory Markers in Hyperlipidemia: From Experimental Models to Clinical Practice
Current Pharmaceutical Design Editorial [Hot Topic:Stabilizing the Vulnerable Plaque: The Search for the Magic Bullet (Executive Editors: G. Pasterkamp and M. Daemen)]
Current Pharmaceutical Design Bioavailability of Quercetin: Problems and Promises
Current Medicinal Chemistry Role of Brain NUCB2/nesfatin-1 in the Regulation of Food Intake
Current Pharmaceutical Design Neuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies
Current Drug Targets